Chelidonium and HIV

For research papers and other publications which do not fit comfortably into the above headings. Also for those who wish to submit reviews or otherwise offer opinions about relevant publications.
Mark
Site Admin
Posts: 893
Joined: 12 Jan 2006, 11:26
Location: Forest of Dean, UK
Contact:

Chelidonium and HIV

Post by Mark »

EFFECT OF Chelidonium majus 6 CH ON METABOLIC ABNORMALITIES IN PEOPLE LIVING WITH HIV / AIDS

ALPP de Paula Soares; NAF Steiner; JB Barbosa; T Sakurada Junior; M Spack Jr; ART Pupulin

ABSTRACT: In Brazil from 1980 to 2012 were identified 656,041 cases of HIV /
AIDS. During these years, 205,409 deaths occurred due to disease. From the nineties,
with the introduction of Highly Active Antiretroviral Therapy (HAART) - was highly
active antiretroviral therapy increased survival and improved quality of life, and provide
partial restoration of the immune system. However as a result of HAART showed the
effects of the combination treatment in the body / virus. These include changes in lipid
metabolism leading to hypertriglyceridemia and other metabolic disorders such as
insulin resistance, hyperglycemia and redistribution of body fat which are risk factors
for cardiovascular disease. These changes are the result of a complex combination of
HIV infection and antiretroviral therapy leading to alterations in lipid metabolism and
hepatic steatosis. The involvement of the liver in patients with AIDS may occur due to
opportunistic infections, cancers and induced by drugs (ARVs). In recent decades
considerable part of the population has used the Complementary and Alternative
Medicine and homeopathy, acupuncture and herbal medicine the most used. Although
homeopathy is one of the most used therapeutic few studies are made towards the
elucidation of their effects. A homeopathic medicine widely used for liver disorders is
Chelidonium majus. The aim of this study was to evaluate the effect of homeopathic
Chelidonium majus on the liver changes of people living with HIV / AIDS. An
experimental study randomized double blind placebo controlled. Clinical evaluation
was performed - monthly laboratory before, during and after treatment. 21 patients with
one or more changes made use of the drug for 16 weeks. Observed decrease in blood
triglyceride levels (p <0.05) was not observed significant changes in other metabolic
changes. This work indicates that Chelidonium majus at the concentration used in any
way alter this dynamic disease, requiring further studies to elucidate this effect.

Keywords: HIV/AIDS, metabolic changes, Chellidonium majus